Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell ...

The life sciences landscape has changed significantly in recent decades, and will continue to do so at pace.1 The rise of ...

Gefurulimab is under clinical development by Alexion Pharmaceuticals and currently in Phase III for Myasthenia Gravis.

Cartesian Therapeutics has a strong cash position after a $130 million equity raise, extending its runway to support upcoming ...

J&J seeks EU approval of nipocalimab to treat people living with generalised myasthenia gravis: Beerse, Belgium Saturday, September 14, 2024, 13:30 Hrs [IST] Janssen-Cilag Interna ...

An inspiring Pemberton woman has opened up about completing the Camino de Santiago in Spain, 30 years after being diagnosed with a chronic autoimmune disorder called myasthenia gravis (MG). Kelly ...

The potential value of these biomarkers may help differentiate acetylcholine receptor antibody seropositive (AChR+) myasthenia gravis (MG) from healthy patients. The potential value of these ...

MG results in weakness of the skeletal muscles and affects the voluntary muscles of the body. Muscles around people’s eyes, ...

Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Hold rating on Kyverna Therapeutics, Inc. (KYTX – Research Report). The ...

Funeral Monday 9:15 AM from the funeral home to Christ the King Church, 1501 S. Main Street, Lombard. Mass 10 AM. Interment Queen of Heaven Cemetery. Memorials to Myasthenia Gravis Foundation of ...

Johnson & Johnson (J&J) has announced that the US Food and Drug Administration (FDA) has accepted its Biologics License ...